Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study from Italy Emphasizing Head and Neck Areas - Scorecard - MDSpire

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study from Italy Emphasizing Head and Neck Areas

  • By

  • Luigi Gargiulo

  • Luciano Ibba

  • Matteo Bianco

  • Sara Di Giulio

  • Mario Valenti

  • Gianluca Avallone

  • Martina Zussino

  • Paolo Calzari

  • Angelo Valerio Marzano

  • Antonio Costanzo

  • Silvia Mariel Ferrucci

  • Alessandra Narcisi

  • March 28, 2026

  • 0 min

Share

Clinical Scorecard: Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study from Italy Emphasizing Head and Neck Areas

At a Glance

CategoryDetail
Condition
Key MechanismsLebrikizumab targets interleukin (IL) 13, blocking its interaction with IL-4Rα and IL-13Rα1, which are critical in Type II inflammation.
Target Population
Care Setting

Key Highlights

  • Sustained effectiveness of lebrikizumab over 52 weeks.
  • Maintenance dosing every 4 weeks (Q4W) was effective.
  • Clinical responses were comparable in patients with and without head and neck involvement.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • P
      • a
      • t
      • i
      • e
      • n
      • t
      • s
      • s
      • h
      • o
      • u
      • l
      • d
      • b
      • e
      • m
      • o
      • n
      • i
      • t
      • o
      • r
      • e
      • d
      • f
      • o
      • r
      • c
      • l
      • i
      • n
      • i
      • c
      • a
      • l
      • r
      • e
      • s
      • p
      • o
      • n
      • s
      • e
      • u
      • s
      • i
      • n
      • g
      • E
      • c
      • z
      • e
      • m
      • a
      • A
      • r
      • e
      • a
      • a
      • n
      • d
      • S
      • e
      • v
      • e
      • r
      • i
      • t
      • y
      • I
      • n
      • d
      • e
      • x
      • (
      • E
      • A
      • S
      • I
      • )
      • s
      • c
      • o
      • r
      • e
      • s
      • a
      • t
      • e
      • a
      • c
      • h
      • v
      • i
      • s
      • i
      • t
      • ,
      • w
      • i
      • t
      • h
      • a
      • f
      • o
      • c
      • u
      • s
      • o
      • n
      • E
      • A
      • S
      • I
      • 7
      • 5
      • ,
      • E
      • A
      • S
      • I
      • 9
      • 0
      • ,
      • a
      • n
      • d
      • E
      • A
      • S
      • I
      • 1
      • 0
      • 0
      • .

      Risks

        Patient & Prescribing Data

        Patients treated with lebrikizumab at two referral centers in Northern Italy.

        Patients received initial doses followed by maintenance dosing based on clinical response.

        Clinical Best Practices

        • Utilize a multidimensional assessment for treatment decisions.
        • Incorporate patient-reported outcomes in monitoring effectiveness.

        References

        Original Source(s)

        Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study from Italy Emphasizing Head and Neck Areas

        • by Luigi Gargiulo, Luciano Ibba, Matteo Bianco, Sara Di Giulio, Mario Valenti, Gianluca Avallone, Martina Zussino, Paolo Calzari, Angelo Valerio Marzano, Antonio Costanzo, Silvia Mariel Ferrucci, Alessandra Narcisi

        • March 28, 2026

        Related Content

        Overview of Findings: Real-World Outcomes of Systemic Therapies for Moderate-to-Severe Atopic Dermatitis in Children Aged 12 and Younger from the PEDISTAD Registry

        Smartwatch May Track AD Status in Children

        Wearable-derived scratching measures align with disease activity and short-term treatment response in pediatric patients with atopic dermatitis.

        Allergen Sensitization in Skin of Color

        Scoping review links contact allergy to AD severity